Ghrelin, the Hunger Hormone: What the Evidence Shows

Ghrelin is the only hormone released from the gut that makes you hungrier. Every other appetite signal the digestive tract produces — GLP-1, peptide YY, cholecystokinin, amylin — tells the brain to stop eating. Ghrelin, discovered in 1999 as the natural activator of the growth hormone secretagogue receptor, does the opposite: it rises before meals, falls after them, and climbs steeply during weight loss. That last property is why the hunger hormone matters far more for maintaining weight loss than for causing obesity in the first place.

The popular framing has it backwards. Articles promising to "lower your ghrelin" assume people with obesity have too much of it. They generally have less.

Evidence: "The ghrelin system comprises the hormones ghrelin and LEAP2, their receptor GHSR, and the enzyme GOAT... Ghrelin was discovered as the endogenous agonist for GHSR in 1999 and earned a reputation for its potent effects to stimulate appetite, reduce energy expenditure, and promote adiposity." — Zigman JM. Diabetes. 2025. DOI: 10.2337/dbi25-0032

What Ghrelin Actually Does

Ghrelin is produced mainly by cells in the fundus of the stomach. Before it can act, an enzyme called GOAT attaches a fatty acid to it — acylation — and only this acylated form binds GHSR1a, the receptor concentrated in hypothalamic nuclei that govern feeding. Unacylated ghrelin circulates in far greater quantity and does something different, which is one reason studies that measure "total ghrelin" and studies that measure "acyl ghrelin" sometimes disagree.

Its effects go beyond appetite. Ghrelin stimulates growth hormone release, raises blood glucose, promotes fat storage, and lowers energy expenditure. During prolonged fasting it functions as a survival signal, defending blood sugar when food is unavailable. That secondary role turns out to matter enormously for anyone hoping to build a drug that blocks it.

The daily rhythm is meal-anticipatory rather than purely reactive. Levels climb in the hour before a habitual eating time and drop sharply once nutrients arrive — which means the pattern is partly learned. Eat lunch at noon for a month and ghrelin will start rising at 11:30 whether or not your body needs the calories.

The Obesity Paradox: Low Ghrelin, High LEAP2

If ghrelin drove obesity, people with obesity would have more of it. Fasting ghrelin is instead generally lower in obesity, and its meal-related fall is blunted, so the swing between hungry and satisfied is compressed.

The other half of the system explains more. LEAP2 — liver-expressed antimicrobial peptide 2 — is an endogenous antagonist and inverse agonist at the same receptor ghrelin uses. It rises after eating and in obesity, and falls with fasting and after bariatric surgery. Ghrelin and LEAP2 are opposing forces on one receptor, which is why the LEAP2-to-ghrelin ratio has become a more informative measure than either hormone alone.

Signal	Direction in obesity	Direction with weight loss	Effect at GHSR
Acyl ghrelin	Lower	Higher	Agonist — stimulates appetite
LEAP2	Higher	Lower	Antagonist/inverse agonist
LEAP2:ghrelin ratio	Higher	Lower	Net tone shifts toward hunger with weight loss

Evidence: "LEAP2 is an endogenous GHSR1a antagonist and inverse agonist... LEAP2 suppresses appetite in both rodents and humans, and optimized analogs are being developed." — Holm SK, Johansen VBI, Clemmensen C. Reviews in Endocrine and Metabolic Disorders. 2026. DOI: 10.1007/s11154-025-10007-4

The pattern parallels leptin resistance in a useful way. Both hormones look like obvious drug targets until you notice which direction they move in obesity, and both turn out to be systems that defend against weight loss far more aggressively than they prevent weight gain.

Why Dieting Raises Ghrelin — and Keeps It High

The single most important finding about ghrelin came from a 2002 study comparing two routes to weight loss. Participants who dieted down by 17% of body weight saw their ghrelin climb; patients who had gastric bypass surgery ended up with dramatically suppressed levels despite losing far more.

Evidence: "Plasma ghrelin levels rose by 24 percent with diet-induced weight loss... In the gastric-bypass group, ghrelin levels were 77 percent lower than in normal-weight controls." — Cummings DE, et al. New England Journal of Medicine. 2002. DOI: 10.1056/NEJMoa012908

A 24% rise is not a transient adjustment. The question of how long it lasts was settled in 2011, when researchers tracked appetite hormones for a full year after a 10-week very-low-energy diet.

Evidence: "Weight loss (mean [±SE], 13.5±0.5 kg) led to significant reductions in levels of leptin, peptide YY, cholecystokinin, insulin and amylin and to increases in levels of ghrelin... One year after initial weight reduction, there were still significant differences from baseline in the mean levels of leptin, peptide YY, cholecystokinin, insulin, ghrelin... as well as hunger." — Sumithran P, et al. New England Journal of Medicine. 2011. DOI: 10.1056/NEJMoa1105816

Twelve months out, with weight partially regained, ghrelin remained elevated and subjective hunger remained higher than before the diet ever started. This is the biological core of metabolic adaptation: the body does not simply lower its energy expenditure after weight loss, it also turns up the signal telling you to eat, and it keeps that signal turned up for at least a year.

Weight-loss maintenance, framed this way, is not a test of willpower against a neutral background. It is a test of willpower against an actively opposing endocrine state.

Surgery, GLP-1 Drugs, and Ghrelin

Sleeve gastrectomy removes the gastric fundus — the tissue that produces most of the body's ghrelin. The hormonal consequence is straightforward and large.

Evidence: Acyl ghrelin "reduced by 80% after 3 months" following sleeve gastrectomy and remained approximately 20% below baseline at 12 months, while Roux-en-Y gastric bypass produced an "insignificant decrease at 6 weeks, with levels rising toward baseline by 3 months." — Alic N, Ayaz A. Medicina (Kaunas). 2025. DOI: 10.3390/medicina61081452

The contrast between the two procedures is instructive. Sleeve gastrectomy removes the ghrelin factory; bypass reroutes the intestine but leaves the fundus in place. Both produce substantial weight loss, so ghrelin suppression is clearly not the only mechanism at work — but it plausibly contributes to why surgical weight loss is harder to reverse than dietary weight loss. That difference is part of what the bariatric surgery versus GLP-1 medication comparison turns on.

GLP-1 receptor agonists work through an entirely separate pathway — slowing gastric emptying and acting on satiety circuits — rather than by lowering ghrelin. This matters for what happens when the drugs stop. Semaglutide and tirzepatide suppress appetite while present; they do not remove the tissue that makes ghrelin or permanently reset its set point, which is consistent with the rapid return of appetite and weight regain after stopping GLP-1 medications. The quieting of food noise that patients describe on these drugs is real, and it is also rented rather than owned.

Can You Lower Ghrelin Through Lifestyle?

Mostly no — and the most common advice gets the direction wrong.

Exercise raises ghrelin, it does not lower it. A 2025 meta-analysis pooling 13 long-term exercise interventions found a substantial increase, alongside the expected reductions in weight and BMI.

Evidence: "Exercise interventions significantly increased ghrelin levels (SMD = 1.16, 95% CI: 0.52–1.80, p < 0.0001)" across 13 interventions in 643 participants, while reducing BMI (SMD = −0.43) and body weight (SMD = −0.54). — Xin X, et al. Frontiers in Nutrition. 2025. DOI: 10.3389/fnut.2025.1518143

Heterogeneity across those trials was high (I² = 90%), so the precise magnitude is uncertain. The direction is not, and it is almost certainly a consequence of fat loss rather than a reason to avoid training. Exercise remains among the best-supported tools for weight maintenance; it simply does not work by calming the hunger hormone.

Sleep has a real but small effect. Short sleep is associated with higher ghrelin, though the size of that association is modest.

Evidence: "Ghrelin levels were higher in the short sleep group" with a standardized mean difference of 0.14 (95% CI 0.03–0.25, p = 0.01), across 21 studies and 2,250 participants. — Lin J, et al. Obesity Reviews. 2020. DOI: 10.1111/obr.13051

An SMD of 0.14 is a small effect, and a more recent pooling of controlled sleep-deprivation trials found no significant ghrelin change at all. Adequate sleep is worth protecting for many reasons; a dramatic ghrelin reduction is not one of the ones the data support.

What has no good evidence: ghrelin-blocking supplements, "ghrelin reset" eating windows, and fasting protocols marketed as retraining the hormone. Fasting raises ghrelin acutely — that is what the meal-anticipatory rhythm does — and no controlled human trial has shown a supplement that meaningfully suppresses acyl ghrelin. What does reliably move ghrelin is body weight itself, in the unhelpful direction.

Why Blocking Ghrelin Failed, and Why LEAP2 Might Not

Two decades of attempts to antagonize ghrelin pharmacologically — receptor blockers, GOAT inhibitors, anti-ghrelin vaccines — produced no approved obesity drug. The reason is the hormone's second job. Ghrelin defends blood glucose during food restriction, and animals with the system fully blocked handle prolonged caloric deficit badly: mice overexpressing LEAP2 became lethargic and unable to maintain stable blood glucose during chronic food restriction, and required growth hormone to recover. A drug that abolishes ghrelin signaling risks abolishing that safety net precisely when a dieting patient needs it.

Native LEAP2 also has a half-life of 10 to 15 minutes, which rules out therapeutic use in its natural form. Extending it changed the calculation. A lipidated long-acting analog reaches a plasma half-life of roughly 5.2 hours, and human infusion studies have now moved from healthy volunteers into the target population.

Evidence: In 20 men with obesity randomized to a ~5-hour intravenous LEAP2 infusion (40 pmol/kg/min) or placebo in a double-blind crossover design, LEAP2 "lowered postprandial plasma glucose levels and reduced ad libitum food intake by ∼12%." — Englund A, et al. Diabetes. 2026. DOI: 10.2337/db25-1132

A 12% reduction in a single test meal, produced by an intravenous infusion in 20 men, is a proof of mechanism and nothing more. It sits several years and several trials away from anything a patient could be prescribed, and partial rather than complete antagonism will likely be the design goal given what full blockade does in animals. The more plausible near-term role is combination — pairing a ghrelin-axis drug with an incretin agonist to blunt the counter-regulatory hunger surge that currently limits how much weight loss any single agent can sustain.

Key Takeaways

Ghrelin is the only gut hormone that increases appetite. It rises before meals, falls after them, and additionally stimulates growth hormone, raises blood glucose, and lowers energy expenditure.
Obesity is a low-ghrelin, high-LEAP2 state. Fasting ghrelin is generally lower in obesity with a blunted post-meal fall, and LEAP2 — the body's own blocker at the same receptor — is elevated.
Dieting raises ghrelin by roughly 24% and keeps it raised. Twelve months after a very-low-energy diet, ghrelin and subjective hunger both remained above pre-diet baseline. This is the endocrine reason maintenance is harder than loss.
Sleeve gastrectomy suppresses ghrelin; gastric bypass largely does not. Acyl ghrelin fell about 80% at three months after sleeve gastrectomy, reflecting removal of the fundus where most ghrelin is made.
GLP-1 medications do not work by lowering ghrelin, which helps explain why appetite returns quickly after stopping them.
Exercise raises ghrelin rather than lowering it, and short sleep raises it only slightly (SMD 0.14). No supplement or eating protocol has been shown to suppress acyl ghrelin in a controlled human trial.
LEAP2 analogs are the credible drug angle, with a first human trial in men with obesity reducing test-meal intake by about 12% — early-stage, and constrained by ghrelin's role in defending blood glucose during food restriction.

The practical value of understanding ghrelin is not a technique for suppressing it. It is knowing that the hunger you feel six months into maintaining a weight loss is a measurable hormonal state rather than a lapse in resolve — and that the interventions worth investing in are the ones that work alongside that signal rather than the ones that claim to switch it off.

References

Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. New England Journal of Medicine. 2002;346(21):1623-1630. DOI: 10.1056/NEJMoa012908
Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. New England Journal of Medicine. 2011;365(17):1597-1604. DOI: 10.1056/NEJMoa1105816
Lin J, Jiang Y, Wang G, et al. Associations of short sleep duration with appetite-regulating hormones and adipokines: a systematic review and meta-analysis. Obesity Reviews. 2020;21(11):e13051. DOI: 10.1111/obr.13051
Zigman JM. From sideshow to center stage: targeting the ghrelin system belongs in the big tent of obesity therapeutics. Diabetes. 2025;74(11):1899-1902. DOI: 10.2337/dbi25-0032
Xin X, Wang H, Guo Y, Xie J. Effect of long-term exercise on circulating ghrelin in overweight and obese individuals: a systematic review and meta-analysis. Frontiers in Nutrition. 2025;12:1518143. DOI: 10.3389/fnut.2025.1518143
Alic N, Ayaz A. Ghrelin and LEAP2: their interaction effect on appetite regulation and the alterations in their levels following bariatric surgery. Medicina (Kaunas). 2025;61(8):1452. DOI: 10.3390/medicina61081452
Holm SK, Johansen VBI, Clemmensen C. LEAP2 as a therapeutic target in obesity and cardiometabolic disorders. Reviews in Endocrine and Metabolic Disorders. 2026;27(3):687-704. DOI: 10.1007/s11154-025-10007-4
Englund A, Lange AH, Hagemann CA, et al. LEAP2 reduces ad libitum food intake and attenuates postprandial glucose excursions in men with obesity. Diabetes. 2026;75(6):925-937. DOI: 10.2337/db25-1132

Last updated: 2026-08-01 Medical review: Dr. James Chen, MD, PhD, FACE